Tag
Shaily Engineering Plastics Limited
6 articles
Shaily Engineering Plastics is experiencing substantial growth driven by its expanding presence in the healthcare sector and strategic diversification initiatives. The company reported a remarkable 128% increase in standalone net profit for FY26, alongside a 26% revenue jump to ₹990.7 crore, fueled by significant orders for pen injectors and EMA approval for Teriparatide. To support further expansion into consumer electronics and semiconductor supply chains, Shaily has secured a ₹423 crore order and approved a resolution to raise up to ₹500 crore, positioning the company for continued momentum and increased investor interest.
Shaily Engineering Plastics Q4 Earnings Call Recording
Shaily Engineering Plastics uploaded audio recording of Q4 earnings call held on 20th May 2026 to company website.
Recording accessible via investor relations section as part of SEBI Listing Regulatio
Shaily Engineering Plastics Launches Semaglutide Pen Injector
Shaily Engineering Plastics announces regulatory approvals for its ShailyPen Neo™ device incorporated in generic Semaglutide injection.
The spring-driven pen injector platform received USFDA tentative
Shaily Engineering Q4 PAT Up 40% YoY
Shaily Engineering reported strong FY26 results with consolidated PAT up 83% YoY to ₹169.9 crore and revenue up 26% to ₹990.7 crore.
The company received a major ₹423 crore order for pen injectors and
Shaily Engineering ESOP Allotment of 40,155 Shares
Shaily Engineering Plastics allotted 40,155 equity shares to employees upon exercise of vested stock options under its 2019 ESOP plan.
The allotment increases the company's paid-up capital from ₹9.19
Shaily Engineering Plastics FY26 Net Profit Up 128% YoY
Shaily Engineering reported audited FY26 standalone net profit of ₹161.32 crore, up 128% YoY from ₹70.91 crore.
Board recommended final dividend of ₹3 (150%) per share of face value ₹2, subject to sha
Shaily Engineering Q4 Net Profit Up 65% YoY
Board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026, reporting significant growth.
Recommended a final dividend of ₹3 (150%) per equity share of fac